Genomic, Proteomic, and Metabolic Comparisons of Small Animal Models of Heart Failure With Preserved Ejection Fraction: A Tale of Mice, Rats, and Cats.
Alex N. Smith,Raffaele Altara,Ghadir Amin,Nada J. Habeichi,Daniel G. Thomas,Seungho Jun,Abdullah Kaplan,George W. Booz,Fouad A. Zouein
DOI: https://doi.org/10.1161/JAHA.122.026071
IF: 6.106
2022-07-30
Journal of the American Heart Association
Abstract:Heart failure with preserved ejection fraction (HFpEF) remains a medical anomaly that baffles researchers and physicians alike. The overall phenotypical changes of diastolic function and left ventricular hypertrophy observed in HFpEF are definable; however, the metabolic and molecular alterations that ultimately produce these changes are not well established. Comorbidities such as obesity, hypertension, and diabetes, as well as general aging, play crucial roles in its development and progression. Various animal models have recently been developed to better understand the pathophysiological and metabolic developments in HFpEF and to illuminate novel avenues for pharmacotherapy. These models include multi‐hit rodents and feline aortic constriction animals. Recently, genomic, proteomic, and metabolomic approaches have been used to define altered signaling pathways in the heart associated with HFpEF, including those involved in inflammation, cGMP‐related, Ca 2+ handling, mitochondrial respiration, and the unfolded protein response in endoplasmic reticulum stress. This article aims to present an overview of what has been learnt by these studies, focusing mainly on the findings in common while highlighting unresolved issues. The knowledge gained from these research models will not simply be of benefit for treating HFpEF but will undoubtedly provide new insights into the mechanisms by which the heart deals with external stresses and how the processes involved can fail. Nonstandard Abbreviations and Acronyms AIU aldosterone‐infused uninephrectomy Fstl1 follistatin like 1 SAHA suberoylanilide hydroxamic acid UPR unfolded protein response ...And you know something's happening but you do not know what it is...Do you, Mr. Jones . Ballad of a Thin Man , by Bob Dylan. Cardiovascular disease remains one of the cardinal areas of health care research and plagues humankind worldwide (https://www.who.int/news‐room/fact‐sheets/detail/cardiovascular‐diseases‐(cvds)). Of the various types of cardiovascular disease, heart failure accounts for roughly 26 million cases of disease burden. Heart failure can be broadly divided into 2 categories: heart failure with reduced ejection fraction (HFrEF) that is governed by systolic dysfunction and ventricular dilation with ejection fractions 55%. 1 , 2 HFrEF is typically the result of direct insult to the myocardial tissue by factors such as myocardial infarction and volume overload. In contrast, HFpEF is initiated by a variety of metabolic altering factors such as hypertension, diabetes, obesity, and aging. With the population on average becoming progressively older, as well as the increased prevalence of common comorbidities, such as obesity and diabetes, it is no surprise that HFpEF is a chief concern in the medical and research communities. 3 Over the course of medical advancement, HFrEF has been successfully managed by numerous neurohormonal interventions, such as β‐adrenergic receptor blockers, angiotensin‐converting enzyme inhibitors, angiotensin II type 1 receptor blockers, and mineralocorticoid receptor agonists. 4 However, there are currently no cause‐based treatments to reduce morbidity and mortality of HFpEF, although a sodium‐glucose cotransporter 2 (SGLT2) inhibitor was recently demonstrated to be effective regardless of the presence or absence of diabetes. 5 In addition, certain patients (females or those in the lower strata for "preserved" ejection fraction, ie, <≈60%) may benefit from treatment with the angiotensin receptor–neprilysin inhibitor sacubitril–valsartan, particularly for heart failure hospitalization. 6 Even though the overall phenotypical changes involving HFpEF are generally well characterized, the underlying genomic, proteomic, and molecular alterations that ultimately lead to HFpEF are rather undetermined. HFpEF has become an object of various preclinical, experimental rodent models in attempts to understand its complex cause. These experimental models use various approaches, including models that are "multi‐hit", diet‐induced, physiological age‐induced, or involve altered gene expression. Recently, an experimental feline model has been described to understand the molecular pathogenesis of HFpEF better. Besides determining the underlying physiological mechanism -Abstract Truncated-
cardiac & cardiovascular systems